Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...

AstraZeneca (NASDAQ:AZN) announced on Wednesday that its experimental breast cancer treatment, camizestrant, helped extend survival without disease progression in patients with an advanced form of the ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug camizestrant significantly delayed disease progression in a phase III trial for advanced hormone receptor-positive breast cancer, ...